Hanxiao You

Hanxiao You

Auto-generated profile, based on publicly available information

Hanxiao You

Dept. of Rheumatology, Peking Union Medical College Hospital, Beijing, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2020 in Clinical Reviews in Allergy & Immunology
Verified
Journal Article
Closed access
PDF file
HYHanxiao You
Hanxiao You
DXDong Xu
Dong Xu
JZJiuliang Zhao
Jiuliang Zhao
JLJing Li
Jing Li
QWQian Wang
Qian Wang
XZXiao-Feng Zeng
Xiao-Feng Zeng


15 June 2022 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
CLChengyin Lv
Chengyin Lv
HYHanxiao You
Hanxiao You
LXLingxiao Xu
Lingxiao Xu
LWLei Wang
Lei Wang
FYFenghong Yuan
Fenghong Yuan
WTWenfeng Tan
Wenfeng Tan
Objective: Interstitial lung disease (ILD) is a common extramuscular complication contributing to significant morbidity and mortality in patients with dermatomyositis (DM) who are positive for antimelanoma differentiation–associated gene 5 antibody (anti-MDA5+). We conducted this study to investigate the association of anti-Ro52 antibodies with clinical characteristics and prognosis in patients with anti-MDA5+ DM.Methods: We assessed a cohort of 246 patients with anti-MDA5+ DM. To calculate hazard ratios and 95% CIs for rapidly progressive ILD (RP-ILD) and death while controlling for potential confounders, variables selected by univariate Cox regression analysis were included in a multivariate Cox regression model with the stepwise forward-selection method. A 2-tailed analysis withP< 0.05 was considered to be statistically significant.Results: A total of 246 patients with anti-MDA5+ DM were enrolled; 70 patients were male, and the patient group had an average age of 53.1 (12.4) years. Anti-Ro52 was present in 64.2% (158/246) patients. Patients with anti-MDA5+ DM who were positive for anti-Ro52 had a higher rate of RP-ILD (log-rankP< 0.001) and a higher mortality rate (log-rankP= 0.01). For patients with anti-MDA5+ DM who were positive for anti-Ro52, those with a short disease course and high inflammation were at increased risk of RP-ILD and death. The appearance of active rash was an independent protective factor of death.Conclusion: Anti-Ro52 antibodies were highly prevalent in patients with anti-MDA5+ DM, and their coexistence correlated with a higher rate of RP-ILD and mortality. Patients with a short disease course, with increased inflammation, and without rash were more likely to have a poor prognosis.

1 October 2019 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
HYHanxiao You
Hanxiao You
GZGuizhi Zhang
Guizhi Zhang
QWQian Wang
Qian Wang
SZShangzhu Zhang
Shangzhu Zhang
JZJiuliang Zhao
Jiuliang Zhao
XZXiao-Feng Zeng
Xiao-Feng Zeng

12 August 2022 in Rheumatology
Verified
Journal Article
Closed access
PDF file
HYHanxiao You
Hanxiao You
LWLei Wang
Lei Wang
JWJiajia Wang
Jiajia Wang
CLChengyin Lv
Chengyin Lv
LXLingxiao Xu
Lingxiao Xu
WTWenfeng Tan
Wenfeng Tan
Objectives: Anti-melanoma differentiation-associated gene 5 positive (anti-MDA5+) DM has a close relationship with rapidly progressive interstitial lung disease (RPILD) and is associated with high mortality. However, data regarding the time-dependent risk of RPILD and deaths during disease progression are limited. We conducted this study to investigate whether the risk of RPILD and death were time-dependent or not in anti-MDA5+ DM.Methods: We assessed a cohort of 272 patients with anti-MDA5+ DM. The clinical characteristics of patients with anti-MDA5+ were collected, and COX regression was used to analyse independent risk factors for RPILD and death. We also described changes in risk of RPILD and death over time and their potential clinical implications.Results: There were 272 anti-MDA5+ DM patients enrolled in this study. According to the multivariate cox regression analysis, short disease course, high CRP level, anti-Ro52 positive and anti-MDA5 titre (++∼+++) were independent risk factors of RPILD. High creatine kinase level, high CRP level and RPILD were independent risk factors for death, and >90% RPILD and 84% mortality occurred in the first 6 months after disease onset. Notably, the first 3 months is a particularly high-risk period, with 50% of RPILD and 46% of deaths occurring. Hazards regarding RPILD and mortality diminished over time during a median follow-up of 12 months.Conclusion: These results suggest significant, time-dependent changes in RPILD and mortality risk in anti-MDA5+ DM patients, providing a cut-off time window to estimate disease progression and poor prognosis.

14 November 2020 in Rheumatology
Verified
Journal Article
Open access
PDF file
HYHanxiao You
Hanxiao You
DXDong Xu
Dong Xu
YHYong Hou
Yong Hou
JZJiaxin Zhou
Jiaxin Zhou
QWQian Wang
Qian Wang
XZXiao-Feng Zeng
Xiao-Feng Zeng
To analyse the effectiveness of tofacitinib for the treatment of refractory skin thickening in dcSSc. Data from 10 patients with dcSSc treated with tofacitinib (5 mg twice daily) were analysed. A total of 12 dcSSc patients treated with intensive conventional immunosuppressants were selected as the historical comparator group. A clinically relevant response was defined as a decrease in the modified Rodnan skin score (mRSS) of >5 points and ≥25% from baseline. Clinical indicators were compared between the two groups to evaluate the effect of tofacitinib. The mRSS significantly improved the first month after tofacitinib treatment, with a mean change in the mRSS of −3.7 (95% CI −5.52, −1.88; P = 0.001) and greater than the comparators at 6 months [−10.0 (95% CI −14.74, −5.26) vs −4.1 (95% CI −7.49, −0.73), P = 0.026]. Tofacitinib-treated patients had a significantly shorter response time than the comparators (P = 0.015 by log-rank test), with overall response rates of 20% (2/10) vs 0% (0/12) and 60% (6/10) vs 16.7% (2/12) at 1 and 3 months, respectively. Our results indicate that tofacitinib may be as effective as or even better than intensive conventional immunosuppressants, with a quicker and higher response rate in refractory dcSSc patients with progressive skin thickness.